Two New Approvals, One Clear Direction — Targeted Drug Therapies Come of Age in 2025
The past year brought two significant FDA approvals that signal where prostate cancer treatment is heading: toward more precise, earlier-acting […]
Recent Advances in Prostate Cancer Treatment
Prostaid Calgary Director Saif Lalani looks at today’s changing landscape for prostate cancer treatment with a deeper look at the following treatments: Darolutamide, Xofigo/Radium 223, and Prostate Specific Membrane Antigen (PSMA), their qualities and their availability today in Canada and beyond.